$SILK
Silk Road Medical Inc

2023 Q3 Form 10-Q Financial Statement

#000139770223000051 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $44.44M $45.30M $33.17M
YoY Change 18.89% 36.55% 25.39%
Cost Of Revenue $12.05M $13.00M $9.012M
YoY Change 29.46% 44.3% 36.59%
Gross Profit $32.39M $32.29M $24.16M
YoY Change 15.39% 33.66% 21.67%
Gross Profit Margin 72.88% 71.29% 72.83%
Selling, General & Admin $36.01M $35.83M $27.70M
YoY Change 24.94% 29.35% 22.84%
% of Gross Profit 111.19% 110.95% 114.65%
Research & Development $10.05M $10.78M $10.66M
YoY Change 18.6% 1.17% 46.74%
% of Gross Profit 31.02% 33.38% 44.1%
Depreciation & Amortization $660.0K $685.0K $502.0K
YoY Change 21.55% 36.45% 107.44%
% of Gross Profit 2.04% 2.12% 2.08%
Operating Expenses $46.06M $46.61M $38.36M
YoY Change 23.5% 21.52% 28.66%
Operating Profit -$13.67M -$14.32M -$14.19M
YoY Change 48.18% 0.86% 42.62%
Interest Expense $1.732M $722.0K -$909.0K
YoY Change 1.05% -179.43% -244.75%
% of Operating Profit
Other Income/Expense, Net -$2.000K $110.0K -$50.00K
YoY Change -150.0% -320.0% 733.33%
Pretax Income -$12.79M -$13.48M -$15.40M
YoY Change 23.95% -12.43% 46.1%
Income Tax
% Of Pretax Income
Net Earnings -$12.79M -$13.48M -$15.40M
YoY Change 23.93% -12.43% 46.1%
Net Earnings / Revenue -28.78% -29.77% -46.42%
Basic Earnings Per Share -$0.33 -$0.35 -$0.44
Diluted Earnings Per Share -$0.33 -$0.35 -$438.2K
COMMON SHARES
Basic Shares Outstanding 38.83M 38.73M 35.12M
Diluted Shares Outstanding 38.87M 38.77M 35.14M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $192.9M $188.4M $108.9M
YoY Change 83.48% 73.01% -15.04%
Cash & Equivalents $29.19M $28.40M $87.64M
Short-Term Investments $163.7M $160.0M $21.23M
Other Short-Term Assets $4.300M $4.543M $4.653M
YoY Change -5.35% -2.36% -20.83%
Inventory $22.07M $19.07M $17.62M
Prepaid Expenses
Receivables $21.78M $21.53M $15.78M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $241.0M $233.5M $146.9M
YoY Change 63.95% 58.93% -7.33%
LONG-TERM ASSETS
Property, Plant & Equipment $8.337M $8.644M $15.38M
YoY Change -13.79% -43.8% 348.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.300M $13.88M
YoY Change
Other Assets $7.196M $7.336M $421.0K
YoY Change 25.56% 1642.52% -92.9%
Total Long-Term Assets $19.88M $29.86M $15.80M
YoY Change 27.79% 88.99% 63.43%
TOTAL ASSETS
Total Short-Term Assets $241.0M $233.5M $146.9M
Total Long-Term Assets $19.88M $29.86M $15.80M
Total Assets $260.9M $263.4M $162.7M
YoY Change 60.49% 61.85% -3.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.094M $5.338M $3.666M
YoY Change 18.14% 45.61% 87.23%
Accrued Expenses $18.93M $18.76M $17.09M
YoY Change -3.53% 9.75% 16.24%
Deferred Revenue $120.0K $220.0K
YoY Change -59.73%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.02M $24.10M $21.24M
YoY Change 0.37% 13.45% 27.47%
LONG-TERM LIABILITIES
Long-Term Debt $75.36M $75.10M $74.03M
YoY Change 1.38% 1.45% 52.29%
Other Long-Term Liabilities $8.336M $8.654M $7.418M
YoY Change 17.86% 16.66% 9.23%
Total Long-Term Liabilities $83.70M $83.76M $81.45M
YoY Change 2.81% 2.83% 47.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.02M $24.10M $21.24M
Total Long-Term Liabilities $83.70M $83.76M $81.45M
Total Liabilities $107.7M $107.9M $102.7M
YoY Change 2.26% 5.03% 42.49%
SHAREHOLDERS EQUITY
Retained Earnings -$386.4M -$373.7M
YoY Change 16.72%
Common Stock $39.00K $39.00K
YoY Change 11.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $153.1M $155.5M $60.03M
YoY Change
Total Liabilities & Shareholders Equity $260.9M $263.4M $162.7M
YoY Change 60.49% 61.85% -3.26%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$12.79M -$13.48M -$15.40M
YoY Change 23.93% -12.43% 46.1%
Depreciation, Depletion And Amortization $660.0K $685.0K $502.0K
YoY Change 21.55% 36.45% 107.44%
Cash From Operating Activities -$6.800M -$4.616M -$10.41M
YoY Change 43.88% -55.64% 15.14%
INVESTING ACTIVITIES
Capital Expenditures $330.0K $434.0K -$977.0K
YoY Change -184.83% -144.42% 21.52%
Acquisitions
YoY Change
Other Investing Activities $7.790M -$18.72M -$21.17M
YoY Change -123.96% -11.57% -241.15%
Cash From Investing Activities $7.450M -$19.16M -$22.15M
YoY Change -122.65% -13.51% -256.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 130.0K 1.592M 26.59M
YoY Change -89.28% -94.01% 1157.26%
NET CHANGE
Cash From Operating Activities -6.800M -4.616M -10.41M
Cash From Investing Activities 7.450M -19.16M -22.15M
Cash From Financing Activities 130.0K 1.592M 26.59M
Net Change In Cash 780.0K -22.18M -5.965M
YoY Change -102.14% 271.87% -182.02%
FREE CASH FLOW
Cash From Operating Activities -$6.800M -$4.616M -$10.41M
Capital Expenditures $330.0K $434.0K -$977.0K
Free Cash Flow -$7.130M -$5.050M -$9.429M
YoY Change 64.4% -46.44% 14.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Central Index Key
EntityCentralIndexKey
0001397702
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38847
dei Entity Registrant Name
EntityRegistrantName
SILK ROAD MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8777622
dei Entity Address Address Line1
EntityAddressAddressLine1
1213 Innsbruck Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94089
dei City Area Code
CityAreaCode
408
dei Local Phone Number
LocalPhoneNumber
720-9002
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
SILK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38832992
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28400000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55358000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
159961000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
158316000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21525000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18007000
CY2023Q2 us-gaap Inventory Net
InventoryNet
19067000
CY2022Q4 us-gaap Inventory Net
InventoryNet
19293000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4543000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3924000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
233496000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
254898000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
13884000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8644000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9372000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
155000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7336000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5260000
CY2023Q2 us-gaap Assets
Assets
263360000
CY2022Q4 us-gaap Assets
Assets
269685000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5338000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2523000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18759000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21965000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
24097000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24488000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
75104000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
74596000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8654000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6726000
CY2023Q2 us-gaap Liabilities
Liabilities
107855000
CY2022Q4 us-gaap Liabilities
Liabilities
105810000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38812280
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38812280
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38355972
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38355972
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
39000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
529453000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
507715000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-331000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-166000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-373656000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-343712000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
155505000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
163875000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263360000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269685000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45298000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33173000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
85429000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
61193000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13004000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9012000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
25530000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17588000
CY2023Q2 us-gaap Gross Profit
GrossProfit
32294000
CY2022Q2 us-gaap Gross Profit
GrossProfit
24161000
us-gaap Gross Profit
GrossProfit
59899000
us-gaap Gross Profit
GrossProfit
43605000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10780000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10655000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21213000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18778000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35830000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
27700000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
69913000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54975000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
46610000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
38355000
us-gaap Operating Expenses
OperatingExpenses
91126000
us-gaap Operating Expenses
OperatingExpenses
73753000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14316000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14194000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31227000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30148000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2434000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
122000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4721000
us-gaap Investment Income Interest
InvestmentIncomeInterest
134000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1712000
CY2022Q2 us-gaap Interest Expense
InterestExpense
1031000
us-gaap Interest Expense
InterestExpense
3405000
us-gaap Interest Expense
InterestExpense
1652000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-245000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-245000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
110000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-50000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-166000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13484000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15398000
us-gaap Net Income Loss
NetIncomeLoss
-29944000
us-gaap Net Income Loss
NetIncomeLoss
-32077000
CY2023Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-414000
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-2000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-165000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-2000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-414000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-165000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13898000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15400000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30109000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32079000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38765166
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38765166
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35143178
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35143178
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38649327
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38649327
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35083569
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35083569
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
163875000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1110000
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
8838000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-16460000
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
249000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
157613000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
232000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1359000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
10199000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-13484000
CY2023Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-414000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
155505000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
79240000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
168000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
4978000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-16679000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
67707000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
322000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1239000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6161000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-15398000
CY2022Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-2000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
60029000
us-gaap Profit Loss
ProfitLoss
-29944000
us-gaap Profit Loss
ProfitLoss
-32077000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
1384000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
922000
us-gaap Share Based Compensation
ShareBasedCompensation
19037000
us-gaap Share Based Compensation
ShareBasedCompensation
11139000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3362000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
64000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
114000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
91000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
552000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
496000
silk Paid In Kind Interest Benefit
PaidInKindInterestBenefit
399000
silk Paid In Kind Interest Benefit
PaidInKindInterestBenefit
474000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-245000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-144000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-175000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
19000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-3000
us-gaap Inventory Write Down
InventoryWriteDown
14000
us-gaap Inventory Write Down
InventoryWriteDown
-3000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3537000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3944000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-213000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-239000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
619000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1242000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
124000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
37000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2735000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1076000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2977000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2620000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-811000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16763000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25131000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
721000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3049000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
114131000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
21173000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
101800000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13052000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24222000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2702000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1729000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
75000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
49000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
970000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2702000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26759000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27113000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22594000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55513000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
110463000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28400000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87869000
us-gaap Interest Paid Net
InterestPaidNet
2892000
us-gaap Interest Paid Net
InterestPaidNet
1087000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
56000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
105000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2504000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
903000
silk Unpaid Debt Issuance Costs
UnpaidDebtIssuanceCosts
119000
us-gaap Use Of Estimates
UseOfEstimates
<span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Use of Estimates</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
155000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2022Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Concentration of Credit Risk, and Other Risks and Uncertainties</span><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, U.S. government securities, U.S. treasury bills, agency bonds/notes and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and six months ended June 30, 2023 and 2022.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of June 30, 2023 and December 31, 2022, a portion of the Company’s cash and cash equivalents was maintained with Silicon Valley Bank, a division of First Citizens Bank, or SVB, and exceeded federally insured limits. Substantially all of the Company’s cash equivalents and investments reside in a custodial account held by a third party, in which SVB Asset Management is the advisor. On March 10, 2023, SVB was shut down and placed under receivership with the Federal Deposit Insurance Corporation, or FDIC, by the California Department of Financial Protection and Innovation. On March 26, 2023, the FDIC announced it had entered into a purchase and assumption agreement with First Citizens Bank &amp; Trust Company under which all of SVB’s deposits were assumed. As of the issuance date of these financial statements, the Company has not experienced any losses on its deposits and all of the Company’s cash deposited with SVB has been accessible to the Company.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company’s accounts receivable are due from a variety of hospitals and medical centers in the United States. As of June 30, 2023 and December 31, 2022, no customer represented 10% or more of the Company’s accounts receivable. For the three and six months ended June 30, 2023 and 2022, there were no customers that represented 10% or more of revenue.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations.</span></p><p dir="ltr" style="font-family: 'Arial', 'sans-serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><span style="white-space:pre-wrap; font-family: 'Arial', 'sans-serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Existing or future devices developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.</span>
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
237000
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
148000
CY2023Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2023Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13484000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15398000
us-gaap Net Income Loss
NetIncomeLoss
-29944000
us-gaap Net Income Loss
NetIncomeLoss
-32077000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38765166
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38765166
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35143178
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35143178
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38649327
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38649327
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35083569
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35083569
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5418288
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5288236
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
202338000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
335000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
202007000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
28162000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
159961000
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
13884000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
202007000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
213641000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
181000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
213474000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
55158000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
158316000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
213474000
CY2022Q4 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
775000
CY2023Q2 silk Cash And Cash Equivalents Fair Value Disclosure Maturing Within One Year
CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
188123000
CY2022Q4 silk Cash And Cash Equivalents Fair Value Disclosure Maturing Within One Year
CashAndCashEquivalentsFairValueDisclosureMaturingWithinOneYear
213474000
CY2023Q2 silk Cash And Cash Equivalents Fair Value Disclosure Maturing After One Year Through Two Years
CashAndCashEquivalentsFairValueDisclosureMaturingAfterOneYearThroughTwoYears
13884000
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
202007000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
213474000
CY2023Q2 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P222D
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
121807000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
335000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
76813000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
181000
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
5937000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4913000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
13130000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
14380000
CY2023Q2 us-gaap Inventory Gross
InventoryGross
19067000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
19293000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
12200000
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
15216000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1669000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1844000
CY2023Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1050000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
973000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
606000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
781000
CY2023Q2 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
847000
CY2023Q2 silk Provisions For Sales Returns
ProvisionsForSalesReturns
573000
CY2022Q4 silk Provisions For Sales Returns
ProvisionsForSalesReturns
540000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
501000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
519000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
220000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
253000
CY2023Q2 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
251000
CY2022Q4 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
249000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
842000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
815000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18759000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21965000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2875000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5719000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
5703000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
45699000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
34517000
CY2023Q2 silk Long Term Debt Gross Before Accretion Of Closing Fees
LongTermDebtGrossBeforeAccretionOfClosingFees
94513000
CY2023Q2 silk Accretion Of Closing Costs
AccretionOfClosingCosts
925000
CY2023Q2 silk Long Term Debt Gross After Accretion Of Closing Fees
LongTermDebtGrossAfterAccretionOfClosingFees
95438000
CY2023Q2 silk Long Term Debt Unpaid Interest
LongTermDebtUnpaidInterest
19513000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
821000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
75104000
CY2023Q2 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P3Y
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2504000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
431000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
379000
us-gaap Operating Lease Cost
OperatingLeaseCost
838000
us-gaap Operating Lease Cost
OperatingLeaseCost
744000
CY2023Q2 silk Operating Lease Cash Paid
OperatingLeaseCashPaid
330000
CY2022Q2 silk Operating Lease Cash Paid
OperatingLeaseCashPaid
146000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19037000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11139000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12325000
silk Operating Lease Cash Paid
OperatingLeaseCashPaid
689000
silk Operating Lease Cash Paid
OperatingLeaseCashPaid
-558000
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M21D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0656
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y11M23D
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7034000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5081000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1669000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1844000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7989000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5998000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9658000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
7842000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
991000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1991000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2130000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2255000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4459000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11826000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2168000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
9658000
CY2023Q2 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
22566000
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2023Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2023Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
533000
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
454000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1216000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1043000
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3839858
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.22
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M28D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
112755000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
19898
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.57
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
176957
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
13974
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
53.72
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3668825
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
44529000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2998381
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
21.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M14D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
44393000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3668825
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
24.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
44529000
silk Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Performance
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPerformance
1
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10198000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6161000
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001397702-23-000051-index-headers.html Edgar Link pending
0001397702-23-000051-index.html Edgar Link pending
0001397702-23-000051.txt Edgar Link pending
0001397702-23-000051-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
silk-20230630.xsd Edgar Link pending
silk-20230630x10q.htm Edgar Link pending
silk-20230630xex10_4.htm Edgar Link pending
silk-20230630xex10_5.htm Edgar Link pending
silk-20230630xex10_6.htm Edgar Link pending
silk-20230630xex31_1.htm Edgar Link pending
silk-20230630xex31_2.htm Edgar Link pending
silk-20230630xex32_1.htm Edgar Link pending
silk-20230630_def.xml Edgar Link unprocessable
silk-20230630_lab.xml Edgar Link unprocessable
silk-20230630_pre.xml Edgar Link unprocessable
silk-20230630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
silk-20230630_cal.xml Edgar Link unprocessable